LNC
CRSP icon

Lincoln National Corp’s CRISPR Therapeutics CRSP Stock Holding History

Lincoln National Corp’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-8,618
Closed -$587K – 219
2024
Q1 		$587K Sell
8,618
-882
-9% -$63.1K 0.01% 691
2023
Q4 		$595K Buy
+9,500
New +$525K 0.01% 617
2021
Q3 		– Sell
-1,590
Closed -$257K – 872
2021
Q2 		$257K Buy
+1,590
New +$193K 0.01% 729
2021
Q1 		– Sell
-1,531
Closed -$234K – 810
2020
Q4 		$234K Buy
+1,531
New +$181K 0.01% 653

Other funds holding CRSP

Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Lincoln National Corp's CRSP Position: Q2 2024 in Review

Lincoln National Corp sold out of CRISPR Therapeutics (CRSP) in Q2 2024, closing a stake of 8,618 shares — an estimated $587K sold.

Lincoln National Corp first reported a position in CRSP in Q4 2020 and held it in 4 quarters. The position peaked at $595K in Q4 2023. 449 funds tracked by Wall St. Rank hold CRSP as of Q2 2024.

  • Lincoln National Corp reported no remaining CRISPR Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Lincoln National Corp sold 8,618 CRISPR Therapeutics shares in Q2 2024, an estimated $587K.
  • Lincoln National Corp first reported a position in CRISPR Therapeutics in Q4 2020 and held it in 4 quarters.
  • Lincoln National Corp's CRISPR Therapeutics position peaked at $595K in Q4 2023.
  • 449 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2024.

Based on Lincoln National Corp's 13F filing for Q2 2024, filed 25 Jul 2024.